 "Zydus Gains FDA Approval for Scopolamine Patch, Tapping .6M Market")
Zydus Lifesciences Ltd has secured final approval from the US FDA to Market its Scopolamine transdermal system, designed to prevent nausea and vomiting in various situations, including after surgery and due to motion sickness. The product, which delivers 1 mg over 3 days, will be manufactured at Zydus’ facility in Ahmedabad. This marks the fifth approval in Zydus’ transdermal portfolio, showcasing the company’s expertise in complex drug delivery systems. According to IQVIA data from June 2024, the Scopolamine transdermal system generated annual sales of USD 69.6 million in the US. This approval reinforces Zydus’ commitment to advancing healthcare solutions and meeting patient needs effectively.
Zydus Lifesciences Ltd has recently announced a significant milestone in its pharmaceutical offerings. On August 30, 2024, the company received final approval from the US Food and Drug Administration (USFDA) to Market its Scopolamine transdermal system, a product designed to prevent nausea and vomiting in various situations. This approval is a notable achievement for Zydus, as it marks the fifth approval in its transdermal portfolio.
The Scopolamine transdermal system, which delivers a dosage of 1 mg over three days, will be manufactured at Zydus’s facility in SEZ, Matoda, Ahmedabad. This innovative drug is commonly used to counteract nausea and vomiting resulting from anesthesia, narcotic pain medications, and surgery, as well as to alleviate symptoms of motion sickness.
According to IQVIA MAT data from June 2024, this product had annual sales of USD 69.6 million in the United States. The success of this approval reinforces Zydus’s capabilities in producing complex drug-device dosage forms and showcases its commitment to improving patient outcomes.
For more updates on Zydus Lifesciences and its pharmaceutical innovations, stay tuned.
Tags: Zydus Lifesciences, Scopolamine, USFDA Approval, Pharmaceuticals, Transdermal System, Nausea Prevention, Drug Manufacturing.
-
What is the Scopolamine transdermal system?
The Scopolamine transdermal system is a patch that helps prevent nausea and vomiting, especially from motion sickness or after surgery. -
Why is the USFDA approval important?
The USFDA approval means that the product has met safety and effectiveness standards in the United States, allowing Zydus Lifesciences to sell it there. -
How does the patch work?
The patch releases scopolamine slowly into the skin, which helps control nausea and motion sickness. -
Where can I use this patch?
You can use the patch on clean, dry skin behind your ear, where it will provide relief for several days. - Are there any side effects?
Like all medications, the patch may cause side effects, such as dry mouth, dizziness, or drowsiness. It’s important to read the information that comes with the patch and consult a doctor if needed.
 "Honda recalls models CB350 and H’ness CB350 for critical sensor and camshaft issues, risking braking failures; free replacements offered.")
